tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Srikripa Devarakonda, 53 are a BUY (96.36%), 2 are a HOLD (3.64%).
Analyst Srikripa Devarakonda, currently employed at TRUIST, carries an average stock price target met ratio of 38.53% that have a potential upside of 35.21% achieved within 104 days.
Srikripa Devarakonda’s has documented 113 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 30-Apr-2025.
Analyst best performing recommendations are on SRRK (SCHOLAR ROCK HOLDING CORP).
The best stock recommendation documented was for KYMR (KYMERA THERAPEUTICS) at 11/3/2023. The price target of $41 was fulfilled within 112 days with a profit of $26.73 (187.32%) receiving and performance score of 16.72.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$67
$3.69 (5.83%)
$68
23 days ago
(30-Apr-2025)
31/43 (72.09%)
$4.34 (6.93%)
179
Hold
$59
$-4.31 (-6.81%)
$70
23 days ago
(30-Apr-2025)
7/7 (100%)
$-3.66 (-5.84%)
46
Hold
$68
$4.69 (7.41%)
$71
1 months 2 days ago
(21-Apr-2025)
8/9 (88.89%)
$11.2 (19.72%)
133
Hold
$65
$1.69 (2.67%)
$69
1 months 29 days ago
(24-Mar-2025)
19/21 (90.48%)
$2.22 (3.54%)
155
Buy
$92
$28.69 (45.32%)
$92
2 months 5 days ago
(18-Mar-2025)
7/11 (63.64%)
$32 (53.33%)
135
Which stock is Srikripa Devarakonda is most bullish on?
Which stock is Srikripa Devarakonda is most reserved on?
What Year was the first public recommendation made by Srikripa Devarakonda?
